Nuwellis, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide standalone fourth-quarter financial results.
Business context
Nuwellis develops, manufactures and sells the Aquadex FlexFlow and SmartFlow systems for ultrafiltration therapy to remove excess fluid from patients, primarily when medical management such as diuretics is inadequate. The company is highly dependent on this single commercial product. Its commercial focus includes critical care, heart failure and pediatrics; U.S. sales are mainly direct, with international sales through distributors.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $8.543 million | $7.921 million |
| Gross profit / gross margin | $4.755 million / 55.7% | $4.491 million / 56.7% |
| Operating expenses | $21.926 million | $24.017 million |
| Operating loss | $17.171 million | $19.526 million |
| Net loss | $14.525 million | $19.554 million |
| Net cash used in operations | $15.149 million | $17.843 million |
- Revenue increased 7.9%, attributed to console sales to new and existing customers, higher circuit sales and service-related revenue. Cost of goods sold rose 10.4%; gross margin consequently declined about one percentage point.
- SG&A fell 7.6% to $17.584 million, and R&D fell 12.8% to $4.342 million. The R&D comparison benefited from a $428,160 technology-license fee expensed in 2021.
- Net loss includes $9.247 million of financing expense and an $11.827 million noncash gain from a change in the fair value of warrant liabilities. The improvement in net loss therefore does not solely reflect operating performance.
- Cash and cash equivalents were $17.737 million and marketable securities were $0.569 million at year-end, $18.306 million combined, versus $24.205 million combined in 2021. Current assets were $22.769 million and current liabilities $4.688 million.
- Operating cash outflow remained substantial. Financing provided $9.423 million, principally from the October 2022 equity offering; investing provided $14.728 million, principally from sales of marketable securities.
- The balance sheet reports $12.316 million of total liabilities, including a $6.868 million warrant liability and lease liabilities. No material conventional borrowing is identified in the supplied financial statements. Contractual lease payments totaled $1.343 million.
- Stockholders’ equity was $12.357 million, down from $25.947 million. Accumulated deficit was $267.417 million. The filing reports basic and diluted loss per share of $83.55 in 2022 versus $285.36 in 2021; share amounts and per-share figures reflect the 1-for-100 reverse split.
Material changes and significant events
- The October 2022 offering generated approximately $11.0 million gross and $9.4 million net, through common stock, convertible preferred stock and warrants. The 1-for-100 reverse stock split became effective in December 2022.
- Warrants associated with the 2022 offering became exercisable after the reporting date. By February 24, 2023, 660,046 warrants had converted into an equal number of common shares at no cash proceeds. Common shares outstanding were 1,206,932 on that date.
- On March 3, 2023, the company established an at-the-market program allowing sales of up to $10 million of common stock, with commissions of up to 3%. This is a subsequent event and could dilute existing shareholders.
- The filing revises 2021 comparative presentation for an immaterial error: certain marketable securities had been classified as cash, and related unrealized gains and cash flows were misclassified. Total current assets were unchanged; prior filings were not amended.
Outlook, risks and other notable matters
- Going concern and funding: The auditor’s report and management disclosure state that recurring losses, negative operating cash flows and the need for additional working capital raise substantial doubt about the company’s ability to continue as a going concern. Management says existing resources are expected to support operations through December 31, 2023, but additional financing may be needed and is not assured. A risk-factor disclosure separately says capital may be needed through the end of fiscal 2024; investors should reconcile these runway statements.
- No quantified revenue or earnings guidance is provided in the supplied filing. Management expects continued losses in the near term and makes profitability dependent on adoption of Aquadex, while continuing investment in sales, clinical research and product development.
- Commercial and reimbursement risks: Adoption is uncertain, the customer base is concentrated, and the ten largest customers generated 50.4% of 2022 revenue. Medicare has not issued a favorable national coverage determination for Aquadex; coverage is partly insurer- and case-specific. A new outpatient therapeutic-ultrafiltration CPT code took effect in 2022.
- Operational and regulatory risks: The company relies on third-party suppliers, including single-source suppliers, and cites inflation and potential supply interruptions. EU certification under the legacy medical-device framework was valid through May 26, 2024; the company planned to apply for certification under the EU MDR.
- Development and clinical evidence: The REVERSE-HF randomized trial was enrolling, the ULTRA-PEDs registry was ongoing, and a dedicated pediatric kidney-replacement device was in development. The filing discusses mixed results across earlier heart-failure trials, including renal-function concerns in CARRESS; the company’s favorable interpretations of later analyses are management’s views, not definitive trial outcomes.
- Audit and controls: The auditor issued an unqualified opinion on the financial statements, while highlighting long-lived-asset impairment assessment and warrant-liability valuation as critical audit matters. Management reported disclosure controls and internal control over financial reporting effective; the auditor did not attest to internal-control effectiveness.
- The filing reports no current legal proceedings or material off-balance-sheet arrangements. No standalone Q4 outlook or forecast is provided.
Important facts for investors to verify
- Cash runway assumptions, especially the different 2023 and fiscal-2024 funding references, and the timing and terms of any required financing.
- Warrant and preferred-stock conversion terms, shares issued after year-end, and potential dilution from the ATM program and other authorized shares.
- Revenue growth, customer concentration, repeat utilization of Aquadex, and progress toward broader reimbursement and outpatient adoption.
- Gross-margin pressure, supplier availability and costs, and whether operating cash burn declines as the business scales.
- Clinical-trial enrollment and outcomes, pediatric-device development milestones, and EU MDR certification progress.